Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b randomized double-blind switch study of F/TAF versus ABC/3TC in virologically suppressed HIV-1 patients
2015-000871-28Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Switch to emtricitabine + tenofovir alafenamide (F/TAF) with Maintain abacavir + lamivudine (ABC/3TC) (2 arms). Primary endpoint: Virologic suppression at Week 48. Started Jun 2015; status: completed.
02
Drugs
emtricitabinetenofovir alafenamideabacavirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2015-000871-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000871-28.